Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Native cat epithelium allergen extract is a biological allergen extract developed by Laboratorios LETI, S.L.U. for the treatment and diagnosis of cat-related allergies. It is produced by extracting naturally occurring proteins from cat dander into a phosphate-buffered saline solution, maintaining the allergens in their unmodified (native) state. The extract contains key IgE-binding proteins such as Fel d 1, Fel d 2, Fel d 3, Fel d 4, and Fel d 7. It is primarily used in allergen-specific immunotherapy (AIT) to induce immune tolerance in individuals with allergic rhinitis or allergic asthma triggered by cat epithelium. In clinical research, it has served as a reference standard to evaluate the biological potency of modified extracts, such as depigmented or polymerized allergoids, using dose-response skin prick testing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on native cat epithelium allergen extract.